as 12-20-2024 4:00pm EST
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.
More About Our ACRS ML Model...
What kind of parameters do you use to train ACRS stocks ML model?
To train our stocks ACRS ML model, we use historical data with over 25 parameters, including volume indicators, volatility indicators, momentum indicators, trend indicators, and other metrics.
How often do you update ACRS ML model?
We update our ML model either weekly or biweekly, depending on the market capitalization of the stocks, using TensorFlow, typically over the weekend.
Why is the accuracy of your ACRS model low?
Unfortunately, our current data provider offers limited historical data, which impacts the accuracy of our ML model. However, as we continue to gather more data over time and add more indicators, we expect the accuracy of our model to improve.
How can I provide and share more data with you to increase your ML model accuracy?
We would greatly appreciate your contribution. Please send an email to [email protected]
Do you offer an ML model for shorter time periods, such as 5 minutes or 15 minutes?
Yes, we offer it for strategy purposes only, with intervals: 1 minute, 2 minutes, 5 minutes, 15 minutes, and 30 minutes etc.
Can I rely on your ML model to make financial decisions regarding buying or selling stocks, or is it only intended for learning purposes?
Our ML model is primarily designed for educational purposes and is not intended to provide financial advice. We strongly recommend consulting with a financial advisor before making any buying or selling decisions.
Share on Social Networks:
Disclaimer
Our ACRS ML model is developed exclusively for educational purposes. Any information presented on this page regarding the '"ACRS Forecast & Prediction for December 22, 2024 Aclaris Therapeutics Inc." should not be considered as financial advice or as a recommendation to buy or sell stocks. It is provided strictly for educational purposes. Investing in stocks involves significant risks, and decisions should be made only after careful consideration and consultation with a qualified financial advisor.